Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) reached a new 52-week high during mid-day trading on Tuesday after Needham & raised their price target on the stock from $58.00 to $72.00. Needham & currently has a positive rating on the stock. Esperion Therapeutics traded as high as $56.44 and last traded at $56.81, with a volume of 2,826,725 shares trading hands. The stock had previously closed at $45.17.

A number of other analysts have also recently issued reports on ESPR. UBS AG reaffirmed a “buy” rating and issued a $57.00 price objective (up from $52.00) on shares of Esperion Therapeutics in a research report on Tuesday, June 27th. BidaskClub cut Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday. Deutsche Bank AG began coverage on Esperion Therapeutics in a research report on Friday, June 23rd. They issued a “buy” rating and a $48.00 price objective for the company. Stifel Nicolaus reaffirmed a “buy” rating and issued a $60.00 price objective (up from $45.00) on shares of Esperion Therapeutics in a research report on Monday, June 26th. Finally, Zacks Investment Research raised Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, May 9th. Eight equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $39.16.

A number of hedge funds have recently added to or reduced their stakes in ESPR. Quantbot Technologies LP purchased a new stake in Esperion Therapeutics during the first quarter valued at $158,000. C WorldWide Group Holding A S purchased a new stake in Esperion Therapeutics during the first quarter valued at $162,000. Princeton Alpha Management LP purchased a new stake in Esperion Therapeutics during the first quarter valued at $205,000. Bank of Montreal Can boosted its stake in Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 6,000 shares during the last quarter. Finally, Aperio Group LLC purchased a new stake in Esperion Therapeutics during the second quarter valued at $249,000. 85.20% of the stock is owned by institutional investors and hedge funds.

The stock’s market capitalization is $1.25 billion. The firm has a 50 day moving average of $44.48 and a 200-day moving average of $33.66.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.62) by $0.30. During the same period in the prior year, the firm posted ($0.62) earnings per share. Equities analysts predict that Esperion Therapeutics, Inc. will post ($6.69) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Esperion Therapeutics, Inc. (NASDAQ:ESPR) Sets New 12-Month High After Analyst Upgrade” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright legislation. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/08/08/esperion-therapeutics-inc-nasdaqespr-sets-new-12-month-high-after-analyst-upgrade.html.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.